Adverse reactions and emergency contraception [2]

Lancet

Volumn 357, Issue 9263, 2001, Pages 1203-

  Grant, Ellen C G ^a  

^a NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; LEVONORGESTREL; NORGESTREL; ORAL CONTRACEPTIVE AGENT;

ACTIVATED PROTEIN C RESISTANCE; ANTIPHOSPHOLIPID SYNDROME; ARTERY INJURY; BREAST CARCINOMA; CEREBROVASCULAR ACCIDENT; CONTRACEPTION; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; GENETIC SUSCEPTIBILITY; HEADACHE; HORMONAL THERAPY; HUMAN; LETTER; MENSTRUAL IRREGULARITY; MIGRAINE; NAUSEA; OVARY CARCINOMA; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; TERATOGENESIS; THROMBOEMBOLISM; VOMITING;

EID: 0035857939     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04345-2     Document Type: Letter

References (5)

1. UK Improves access to "morning after pill"
2. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception
3. The pill, hormone replacement therapy, vascular and mood over-reactivity, and mineral imbalance
4. Risk of idiopathic venous thromboembolism in users of progestagens alone
5. Preliminary evaluation of four oral contraceptives containing only progestogens